← Human Trials & Peer-Reviewed Studies
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
Plain-language guide to PMID 20109208 (2010): double-blind randomized controlled trial study of Exenatide, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 20109208
- Journal
- Cardiovascular diabetology
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Gill A et al. (9 authors)
- DOI
- 10.1186/1475-2840-9-6
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Exenatide in the context of low blood pressure and orthostatic hypotension.
Their aim was to assess the effects of the glucagon-like peptide-1 receptor agonist exenatide on heart rate (HR) and blood pressure (BP) in subjects with type 2 diabetes mellitus (T2DM).
Who Took Part
In this double-blind, placebo-controlled trial, subjects with T2DM on metformin and/or a thiazolidinedione were randomized to receive exenatide (5 microg for 4 weeks followed by 10 microg) or placebo BID for 12 weeks.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and pilot study.
Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Exenatide.
The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger Exenatide study would be practical.
The timeline in the abstract includes 4 weeks.
Heart rate and BP were assessed with 24-hour ambulatory BP monitoring.
The primary measure was change from baseline in mean 24-hour HR.
What Was Measured
The subject headings attached to it are Blood Pressure, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin, Heart Rate, Hypoglycemic Agents and Monitoring, Ambulatory.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exenatide in people with low blood pressure and orthostatic hypotension over 4 weeks.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2010 (Cardiovascular diabetology), a journal based in England.
More context: the Exenatide compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.